Atrial natriuretic peptide therapy and in-hospital mortality in acute myocardial infarction patients undergoing percutaneous coronary intervention

Isogai, Toshiaki; Matsui, Hiroki; Tanaka, Hiroyuki; Fushimi, Kiyohide; Yasunaga, Hideo

doi:10.1016/j.ijcard.2016.07.159

Cited by 10 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMI can be classified into acute ST-segment elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI). Cardiovascular disease is the most common disease in elderly and also one of the indexes reflecting the prognosis of patients with acute coronary syndrome; aging is an important risk factor of the occurrence and development of coronary heart disease 3,4. Cardiac failure is usually induced after the occurrence of AMI in the elderly.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure

Wang

Meng

et al. 2017

Pak J Med Sci

View full text Add to dashboard Cite

Objective:To investigate the effects and safety of recombinant human brain natriuretic peptide (rhBNP) in the treatment of elderly acute myocardial infarction induced cardiac failure.Methods:One hundred and forty-six patients who were diagnosed as elderly acute myocardial infarction induced cardiac failure in the hospital from July 2014 to July 2015 were selected. They were divided into a test group and a control group, 73 each. Patients in both groups were given conventional treatment such as stabilization of atherosclerotic plaques, anti-platelet and remodeling and reversion of myocardium. The curative effects and the incidence of adverse reactions of the two groups were observed.Results:The overall efficacy of the test group and the control group was 87.7% and 65.8% respectively, and the difference had statistical significance (P<0.05). The heart rate, urine volume, n-terminal pro-brain natriuretic peptide level and left ventricular ejection fraction (LVEF) of both groups significantly improved after treatment, and the improvement of the test group was superior to that of the control group (P<0.05). The serum creatinine of the test group remarkably reduced after treatment (P<0.05). The incidence of hypotension and arrhythmia of the test group was lower than that of the control group during hospitalization period (P<0.05).Conclusion:rhBNP can effectively relieve the clinical symptoms, cardiac function indexes and hemodynamic indexes of patients with elderly acute myocardial infarction induced cardiac failure, with a high safety. It can be extensively applied in the treatment of acute myocardial infarction in combination with cardiac failure.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure

Wang

Meng

et al. 2017

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…The median length of hospital stay was not significantly different in patients with S-ICD and TV-ICD (13 days [IQR: 10-20.5] vs 12 days [IQR: [10][11][12][13][14][15][16][17][18]). The prevalence of in-hospital complications after ICD implantation was similar between the groups: lead removal (0 vs 2), blood transfusion (0 vs 1), and heart failure (2 vs 3).…”

Section: Discussionmentioning

confidence: 95%

“…These diagnoses are coded using the International Classification of Diseases, Tenth Revision codes (ICD‐10) with text data entered in Japanese. Several studies analyzing this database have been reported in the cardiovascular research field previously …”

Section: Methodsmentioning

confidence: 99%

Patient characteristics and in‐hospital complications of subcutaneous implantable cardioverter‐defibrillator for Brugada syndrome in Japan

Kawamura

Nakajima

Kitamura

et al. 2019

Journal of Arrhythmia

Self Cite

View full text Add to dashboard Cite

BackgroundClinical features and complications of subcutaneous implantable cardioverter‐defibrillator (S‐ICD) implantation for Brugada syndrome have not been well studied.MethodsWe used the Japanese Diagnosis Procedure Combination database to retrospectively investigate patients who had undergone ICD implantation between April 2016 and March 2017. We compared the characteristics and in‐hospital complications of patients with Brugada syndrome implanted with S‐ICD or transvenous (TV)‐ICD.ResultsWe extracted 3090 patients who received ICD implantation. Among them, we identified 278 Brugada patients. The mean age was 43 ± 14.4 years and 262 (94%) were male. Of these 278 patients, 136 (49%) received S‐ICD and 142 (51%) received TV‐ICD. TV‐ICD recipients had a history of atrial fibrillation more frequently compared with S‐ICD recipients. The median (interquartile range) of length of hospital stay was not significantly different between patients with S‐ICD and TV‐ICD (13 days [10‐20.5] vs 12 days [10‐18], respectively). The prevalence of in‐hospital complications after ICD implantation was similar between the two groups. There were no patients with cardiac tamponade, hemothorax, pneumothorax, cardiovascular event, stroke, and death following the procedure during hospitalization in either group.ConclusionsShort‐term safety of S‐ICD implantation may be identical to that of TV‐ICD. Large prospective studies are warranted to compare the effects and long‐term safety of S‐ICD compared with TV‐ICD.

show abstract

“…Diagnoses were recorded with the International Classification of Diseases, Tenth Revision (ICD‐10) codes along with text data entered in Japanese. Several studies in which this database was analyzed have been reported in the cardiovascular research field 13,14 …”

Section: Methodsmentioning

confidence: 99%

Patient characteristics, procedure details including catheter devices, and complications of catheter ablation for ventricular tachycardia: a nationwide observational study

Kitamura

Nakajima

Kawamura

et al. 2020

Journal of Arrhythmia

Self Cite

View full text Add to dashboard Cite

Background: Nationwide data are insufficient with respect to the characteristics of patients undergoing ventricular tachycardia (VT) ablation, complications of VT ablation, and procedure details including catheter devices used during VT ablation. The present study was performed to describe the patient characteristics, procedure details including catheter devices, and in-hospital complications of catheter ablation for VT using a national inpatient database. Methods:We used the Diagnosis Procedure Combination database, a national Japanese inpatient database, to identify patients who underwent VT ablation from July 2010 to March 2017. We examined patients' age, gender, baseline diseases, comorbid conditions, admission status, catheter devices and drugs used, and in-hospital complications of VT ablation. Results:We identified 10 641 patients (median age, 61 years) who underwent VT ablation. The most frequently observed background heart disease among patients with structural heart disease was ischemic cardiomyopathy. An irrigated ablation catheter was used in 73% of patients, a force-sensing ablation catheter was used in 22%, and intracardiac echocardiography was used in 25%. The frequency of using these procedures continuously increased over time. Overall, the prevalence of in-hospital complications was 3.5% (cardiac tamponade, 0.8%; stroke, 0.6%; critical bleeding, 1.9%; mechanical circulatory support, 0.9%; and in-hospital death, 0.8%). Conclusions: The results of this study show the clinical features of VT ablation in a real-world clinical setting. The use of irrigated catheters, force-sensing catheters, and intracardiac echocardiography increased over time. The prevalence of in-hospital complications was 3.5%. K E Y W O R D S catheter ablation, Diagnosis Procedure Combination database, nationwide observational study, ventricular tachycardia | 465 KITAMURA eT Al.

show abstract

Atrial natriuretic peptide therapy and in-hospital mortality in acute myocardial infarction patients undergoing percutaneous coronary intervention

Cited by 10 publications

References 30 publications

Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure

Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure

Patient characteristics and in‐hospital complications of subcutaneous implantable cardioverter‐defibrillator for Brugada syndrome in Japan

Patient characteristics, procedure details including catheter devices, and complications of catheter ablation for ventricular tachycardia: a nationwide observational study

Contact Info

Product

Resources

About